August 29th 2025
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
Gallus BioPharmaceuticals Uses ambr15 Micro Bioreactor to Develop Novel Antibodies and Biosimilars
April 30th 2014TAP Biosystems announced that Gallus BioPharmaceuticals is using its ambr15 micro bioreactor system to optimize process development and clone selection of novel antibody therapeutics and biosimilars.